Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
- Conditions
- Lung Adenocarcinoma
- Interventions
- Other: CT, PET, copy number alteration
- Registration Number
- NCT01482585
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
to determine the values of imaging and genetic biomarkers for prediction of tumor aggressiveness and prognosis in patient with early stage lung adenocarcinoma to Identify unique copy number alteration in patient with early stage lung adenocarcinoma to evaluate the long-term change of ground-glass nodule combined with lung adenocarcinoma to suggest a guideline for planning an appropriate follow-up examination and management
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- A. Clinically and radiologically suspected lung adenocarcinoma
- B. Newly-diagnosed Stage I or II from the clinical work up including PET/CT
- C. Performance status of 0 to 1 on the ECOG scale
- D. Age 20 years or older
- E. Able to tolerable DECT imaging required by protocol
- F. Able to give study-specific informed consent
Exclusion Criteria
- A. Prior malignancy
- B. planning of Definitive RTx 나 neoadjuvant CCRTx
- C. Poor cardiopulmonary reserve
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description early stage lung adenocarcinoma CT, PET, copy number alteration -
- Primary Outcome Measures
Name Time Method Prediction of tumor aggressiveness five years
- Secondary Outcome Measures
Name Time Method prognosis of early stage lung adenocarcinoma following operation five years
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of